Literature DB >> 10925258

T cell reactivity with allergoids: influence of the type of APC.

H Kahlert1, E Grage-Griebenow, H T Stüwe, O Cromwell, H Fiebig.   

Abstract

The use of allergoids for allergen-specific immunotherapy has been established for many years. The characteristic features of these chemically modified allergens are their strongly reduced IgE binding activity compared with the native form and the retained immunogenicity. T cell reactivity of chemically modified allergens is documented in animals, but in humans indirect evidence of reactivity has been concluded from the induction of allergen-specific IgG during immunotherapy. Direct evidence of T cell reactivity was obtained recently using isolated human T cells. To obtain further insight into the mechanism of action of allergoids, we compared the Ag-presenting capacity of different APC types, including DC and macrophages, generated from CD14+ precursor cells from the blood of grass pollen allergic subjects, autologous PBMC, and B cells. These APC were used in experiments together with Phl p 5-specific T cell clones under stimulation with grass pollen allergen extract, rPhl p 5b, and the respective allergoids. Using DC and macrophages, allergoids exhibited a pronounced and reproducible T cell-stimulating capacity. Responses were superior to those with PBMC, and isolated B cells failed to present allergoids. Considerable IL-12 production was observed only when using the DC for Ag presentation of both allergens and allergoids. The amount of IL-10 in supernatants was dependent on the phenotype of the respective T cell clone. High IL-10 production was associated with suppressed IL-12 production from the DC in most cases. In conclusion, the reactivity of Th cells with allergoids is dependent on the type of the APC.

Entities:  

Mesh:

Substances:

Year:  2000        PMID: 10925258     DOI: 10.4049/jimmunol.165.4.1807

Source DB:  PubMed          Journal:  J Immunol        ISSN: 0022-1767            Impact factor:   5.422


  6 in total

Review 1.  [Specific immunotherapy for allergic rhinitis. Current methods and innovative developments].

Authors:  O Pfaar; L Klimek
Journal:  HNO       Date:  2008-08       Impact factor: 1.284

Review 2.  Allergen specific sublingual immunotherapy in children with asthma and allergic rhinitis.

Authors:  Ivana Đurić-Filipović; Marco Caminati; Gordana Kostić; Đorđe Filipović; Zorica Živković
Journal:  World J Pediatr       Date:  2016-06-29       Impact factor: 2.764

3.  Reduced in vitro T-cell responses induced by glutaraldehyde-modified allergen extracts are caused mainly by retarded internalization of dendritic cells.

Authors:  Bärbel Heydenreich; Iris Bellinghausen; Steffen Lorenz; Helene Henmar; Dennis Strand; Peter A Würtzen; Joachim Saloga
Journal:  Immunology       Date:  2012-06       Impact factor: 7.397

Review 4.  Antigen-specific tolerance in immunotherapy of Th2-associated allergic diseases.

Authors:  Charles B Smarr; Paul J Bryce; Stephen D Miller
Journal:  Crit Rev Immunol       Date:  2013       Impact factor: 2.214

Review 5.  Vaccine development for allergen-specific immunotherapy based on recombinant allergens and synthetic allergen peptides: Lessons from the past and novel mechanisms of action for the future.

Authors:  Rudolf Valenta; Raffaela Campana; Margit Focke-Tejkl; Verena Niederberger
Journal:  J Allergy Clin Immunol       Date:  2016-02       Impact factor: 10.793

6.  Depigmented-polymerised allergoids favour regulatory over effector T cells: enhancement by 1α, 25-dihydroxyvitamin D3.

Authors:  Zoe L Urry; David F Richards; Cheryl Black; Maria Morales; Jerónimo Carnés; Catherine M Hawrylowicz; Douglas S Robinson
Journal:  BMC Immunol       Date:  2014-05-29       Impact factor: 3.615

  6 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.